Inhibrx Biosciences Inc 뉴스 - INBX | 주식 나스닥 | ADVFN

다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Inhibrx Biosciences Inc (INBX)
Inhibrx Biosciences Inc (INBX) 뉴스

Inhibrx Biosciences Inc (INBX)

12.49

-0.07

(-0.56%)

마감 25 2월 6:00AM

12.49

0.01

(0.08%)

시간외 거래: 7:25AM

포트폴리오 강화: 실시간 토론 및 실행 가능한 거래 아이디어.

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form PREM14A - Preliminary proxy statements relating to merger or acquisition

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results PR Newswire SAN DIEGO, Feb. 28, 2024 SAN...

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Kuehn Law Encourages DOC, BATL, KAMN, and INBX Investors to Contact Law Firm

Kuehn Law Encourages DOC, BATL, KAMN, and INBX Investors to Contact Law Firm PR Newswire NEW YORK, Jan. 26...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B PR Newswire SAN DIEGO...

1
2
3
다음

Monksdream

Monksdream 4 월 전

Monksdream

Monksdream 5 월 전

Monksdream

Monksdream 6 월 전

Monksdream

Monksdream 11 월 전

TrendTrade2016

TrendTrade2016 2 년 전

heres the dolla...boom!!

TrendTrade2016

TrendTrade2016 2 년 전

INBX DOLLA RUMMER IN PROCESS

TrendTrade2016

TrendTrade2016 2 년 전

INBX...PRE MARKET VOL

Jaydixson1

Jaydixson1 2 년 전

Seems to be dropping

make it happen

make it happen 2 년 전

Numbers do not make sense. They need to raise so much to keep the Phases going. So much debt and money burn with worse quarters and barley any revs. Not bashing it's just what it is. 1,000's of percent's negative on profit. Revenue $0.18 Book Value -$0.12. Also imo this volume isn't sustainable 9 times normal as of now

Profitability
Profit Margin 0.00%
Operating Margin -1,448.76%

Management Effectiveness
Return on Assets -37.98%
Return on Equity -562.25%

Income Statement
Revenue 7.03M
Revenue Per Share 0.18
Quarterly Revenue Growth (yoy) -25.50%
Gross Profit -64.21M
EBITDA -100.6M
Net Income Avi to Common -110.75M
Diluted EPS -2.44

Balance Sheet
Total Debt 175.7M
Book Value Per Share -0.13

Cash Flow Statement
Operating Cash Flow -90.16M
Levered Free Cash Flow -46.31M

Inhibrx Biosciences

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관